Source: https://www.legislation.gov.au/Details/F2014L00588
Timestamp: 2019-03-26 08:35:53
Document Index: 82178387

Matched Legal Cases: ['art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1']

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2014 (No. 5) (No. PB 36 of 2014)
Details: F2014L00588
- F2014L00588
PB 36 of 2014 Lists as made
This instrument amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (No. PB 71 of 2012 to include additions, deletions and changes to forms, brands, responsible person codes, maximum quantities, the circumstances for prescribing various pharmaceutical benefits (including authority requirements), determined quantities, pack quantities and section 100 only status.
Date of repeal 02 Jun 2014
PB 36 of 2014
(1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2014 (No. 5).
(2) This Instrument may also be cited as PB 36 of 2014.
This Instrument commences on 1 June 2014.
[1] Schedule 1, entry for Alendronic acid with colecalciferol in the form Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol
[2] Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 5 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium)
[3] Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 5 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium)
[4] Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 5 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium)
[5] Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 5 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium)
[6] Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 10 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium)
[7] Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 10 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium)
[8] Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 10 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium)
[9] Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 10 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium)
[10] Schedule 1, entry for Arginine with carbohydrate in each of the forms: Sachets of oral powder 4 g containing 500 mg arginine, 30 (Arginine 500); and Sachets of oral powder 4 g containing 2 g arginine, 30 (Arginine 2000)
omit from the column headed “Circumstances”: C1458 substitute: C4555
[11] Schedule 1, after entry for Arginine with carbohydrate in the form Sachets of oral powder 4 g containing 2 g arginine, 30 (Arginine 2000)
[12] Schedule 1, entry for Candesartan in each of the forms: Tablet containing candesartan cilexetil 4 mg; Tablet containing candesartan cilexetil 8 mg; Tablet containing candesartan cilexetil 16 mg; and Tablet containing candesartan cilexetil 32 mg
[13] Schedule 1, entry for Candesartan with Hydrochlorothiazide in the form Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg
[14] Schedule 1, entry for Candesartan with Hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg
[15] Schedule 1, entry for Candesartan with Hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg
[16] Schedule 1, entry for Codeine with Paracetamol [Maximum Quantity: 20; Number of Repeats: 0]
Paracetamol/ Codeine GH 500/30
[17] Schedule 1, entry for Codeine with Paracetamol [Maximum Quantity: 60 CN2064; Number of Repeats: 0]
[18] Schedule 1, entry for Diltiazem in the form Tablet containing diltiazem hydrochloride 60 mg
[19] Schedule 1, entry for Enalapril in each of the forms: Tablet containing enalapril maleate 5 mg; and Tablet containing enalapril maleate
[20] Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL
(a) omit from the column headed “Brand”: Epirubicin Actavis 100 substitute: Epirubicin ACT
(b) omit from the column headed “Responsible Person”: TA substitute: VN
[21] Schedule 1, entry for Everolimus in each of the forms: Tablet 5 mg; and Tablet 10 mg
insert in numerical order in the column headed “Circumstances”: C4557
[22] Schedule 1, entry for Exemestane
APO‑Exemestane
C1541 C2457 C4552
Exemestane‑GA
[23] Schedule 1, after entry for Fentanyl in the form Transdermal patch 16.8 mg [Brand: Fentanyl Sandoz]
[24] Schedule 1, entry for Gemfibrozil
[25] Schedule 1, after entry for Glucose Indicator—Blood in the form Test strips, 100 (FreeStyle Optium)
Test strips, 100 (GoodLife)
[26] Schedule 1, entry for Lactulose
Lac‑Dol
[27] Schedule 1, entry for Lamotrigine in the form Tablet 50 mg
[28] Schedule 1, entry for Mycophenolic Acid in the form Capsule containing mycophenolate mofetil 250 mg
[29] Schedule 1, entry for Mycophenolic Acid in the form Tablet containing mycophenolate mofetil 500 mg
[30] Schedule 1, entry for Nandrolone Decanoate
[31] Schedule 1, entry for Oestriol in each of the forms: Pessaries 500 micrograms, 15; and Vaginal cream 1 mg per g, 15 g
[32] Schedule 1, after entry for Phenoxybenzamine in the form Capsule containing phenoxybenzamine hydrochloride 10 mg
Capsule containing 10 mg phenoxybenzamine hydrochloride
C1239 C1285
[33] Schedule 1, entry for Phenoxybenzamine
[34] Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated) [Maximum Quantity: 30; Number of Repeats: 2]
Rabeprazole RBX
[35] Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated) [Maximum Quantity: 30; Number of Repeats: 5]
[36] Schedule 1, entry for Risperidone in the form Tablet 2 mg [Maximum Quantity: 60; Number of Repeats: 2]
[37] Schedule 1, entry for Risperidone in the form Tablet 2 mg [Maximum Quantity: 60; Number of Repeats: 5]
[38] Schedule 1, entry for Risperidone in the form Tablet 3 mg
[39] Schedule 1, after entry for Tamoxifen in the form Tablet 20 mg (as citrate) [Brand: Tamoxifen Sandoz]
[40] Schedule 3, after details relevant to Responsible Person code JJ
JNS Biomedical Pty Ltd
79 163 593 833
[41] Schedule 3, after details relevant to Responsible Person code VI
Vifor Pharma Pty Limited
87 086 114 043
[42] Schedule 4, Part 1, entry for Arginine with carbohydrate
[43] Schedule 4, Part 1, entry for Everolimus
[44] Schedule 4, Part 1, entry for Exemestane
[45] Schedule 4, Part 1, entry for Plerixafor [Circumstances Code: 4549]
Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per millilitre or less than 10 million per litre on the day of planned collection; OR
[46] Schedule 4, Part 1, entry for Plerixafor [Circumstances Code: 4550]
[47] Schedule 4, Part 1, after entry for Tamoxifen